Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Scores machine (provisoires)
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
- Écart entre enseignants
- 0,186 · la distance entre les deux têtes enseignantes sur ce seul travail
- Statut de validation
score_only:v0-immature-baseline· tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle
Résumé
The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and $^{123}$iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Newcastle University ePrints (Newcastle Univesity)
- Thématique
- Neurology and Historical Studies
- Domaine
- Neuroscience
- Établissements canadiens
- —
- Organismes subventionnaires
- National Institute for Dementia ResearchNational Institute of Neurological Disorders and StrokeNIHR Newcastle Biomedical Research CentreProgramme Grants for Applied ResearchNational Health and Medical Research CouncilMedical Research CouncilCanadian Institutes of Health ResearchHouston Methodist Research InstituteAvid RadiopharmaceuticalsPerelman School of Medicine, University of PennsylvaniaGenentechQatar Biomedical Research Institute, Hamad Bin Khalifa UniversityStifterverbandMinistero dello Sviluppo EconomicoEisaiH. Lundbeck A/SUniversité de StrasbourgMinistero della SaluteBundesministerium für Bildung und ForschungUniversity College LondonCentre National de la Recherche ScientifiqueKing's College LondonUniversity of ExeterNational Institute for Health and Care ResearchSunnybrook FoundationFORUM PharmaceuticalsUniversity of OxfordACADIA PharmaceuticalsParkinson's FoundationFondation Brain CanadaFlorida Atlantic UniversityRush UniversityPfizerUniversity of WashingtonTeva Pharmaceutical IndustriesBristol-Myers SquibbCleveland ClinicCurePSPMassachusetts General HospitalLittle Family FoundationU.S. Department of Veterans AffairsUniversity of PennsylvaniaKanazawa UniversityDemensförbundetFlorida Department of HealthAlzheimer's AssociationThomas Jefferson UniversityCHDI FoundationInternational Parkinson and Movement Disorder SocietyBiogenUniversidad del AtlánticoUniversity of California, San DiegoHouston Methodist HospitalNewcastle UniversityHeart and Stroke Foundation of CanadaNewcastle upon Tyne Hospitals NHS Foundation TrustU.S. Department of Health and Human ServicesTauRx PharmaceuticalsGlaxoSmithKlineWeston Brain InstituteNational Institutes of HealthAlzheimer's Drug Discovery FoundationDeutsche Parkinson VereinigungSanofiDaiichi Sankyo EuropeCalifornia Institute for Regenerative MedicineEli Lilly and CompanyUniversity of TorontoNihon Medi-PhysicsUniversity of North Carolina at Chapel HillVan Andel Research Institute
- Mots-clés
- Dementia with Lewy bodiesDementiaMedicineLibrary scienceComputer sciencePathologyDisease
- Résumé présent dans OpenAlex
- oui